HOME   |    PDF   |   


Title

Symptom burden, mental health and quality of life among COVID-associated mucormycosis patients: A prospective cohort study

 

Authors

Karanvir Singh Matharoo*1, Sushma Bhatnagar2, Shoibam Jenifa3, Rohan Chauhan4 & Santenna Chenchula*5

 

Affiliation

1Department of palliative medicine, Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, Andhra Pradesh, India; 2Department of Medicine, Clinical lead and senior consultant, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India; 3Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Mangalagiri, Guntur, Andhra Pradesh, India; 4Department of Medicine, Fortis Hospital, Ludhiana, India; 5Department of Pharmacology, AIIMS Bhopal, India; *Corresponding author

 

Email

Karanvir Singh Matharoo - E-mail: singhkaranvir328@gmail.com
Sushma Bhatnagar - E-mail: sushmabhatnagar1@gmail.com
Shoibam Jenifa - E-mail: shoibam60@gmail.com
Rohan Chauhan - E-mail: chauhandude12@gmail.com
Santenna Chenchula - E-mail: csanten7@gmail.com

 

Article Type

Research Article

 

Date

Received August 1, 2025; Revised August 31, 2025; Accepted August 31, 2025, Published August 31, 2025

 

Abstract

COVID-associated mucormycosis (CAM) is a severe fungal infection with lasting physical and psychological effects. This prospective cohort of 53 CAM patients evaluated symptom burden, depression (PHQ-9), anxiety (GAD-7), and quality of life (WHOQOL-BREF) at baseline, 6 months and 1 year. Facial pain (89%) and headache (87%) were the most common symptoms; depression improved significantly (PHQ-9: 9.7 to 5.4; p < 0.001), while anxiety initially declined but rose again at 1 year. Quality of life improved in physical and psychological domains, whereas social and environmental aspects remained unchanged. Persistent challenges such as dysphagia (33%), voice changes (27%) and appearance concerns (27%) underscore the need for integrated long-term mental health and rehabilitation strategies in CAM care.

 

Keywords

Mucormycosis; COVID-19; depression; anxiety; mental health; quality of life

 

Citation

Matharoo et al. Bioinformation 21(8): 2272-2277 (2025)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.